ACNT

ACNT is no longer the company its revenue history suggests. After selling BRISMET (~$45M) and ASTI (~$16M) in 2025, the $335M-to-$74.9M revenue collapse from 2021 is a deliberate exit from commodity metals, not a failing business — so the headline -7.2% revenue decline and 169.6x P/E are noise. What remains is a small specialty-chemicals platform (surfactants, defoamers, flame retardants across three plants) that is genuinely healthier on the margin line: gross profit rose 61% to $17.2M and gross margin expanded to 23.0% from roughly 14% even as sales shrank, and FY2025 net income swung positive to $867K from -$13.6M. The balance sheet is the standout — $57.6M cash (up 258% on divestiture proceeds), $87.0M equity, no long-term debt, and liabilities/equity of just 0.29x. Management is returning that cash: $9.14M of buybacks (+781%) cut the share count 6%, consistent with the MD&A's stated 'return excess cash over time to shareholders.'

The problem is that operations still don't pay. Operating income was -$7.03M (-9.4% margin) and the MD&A discloses $7.27M of cash used in continuing operations, a swing from +$0.98M in 2024, driven by working-capital moves (lower inventory turns, falling payables). The tiny positive net income is not operating quality — it leans on divestiture-related items and interest on the cash pile, not core earnings. R&D of $71K against a business that markets itself as a 'performance-driven' specialty formulator is strikingly thin and raises doubt about durable differentiation. So the fortress balance sheet and aggressive buybacks put a floor under the stock, but the turnaround to real operating profitability is asserted, not yet demonstrated.